Vivacitas was formed in 2015, with the vision of our founders and Dr. Joseph Rubinfeld (co-founder of Amgen). Vivacitas is committed to creating new treatment options and improving the lives of cancer patients with solid tumors worldwide.
Cancer is the second leading cause of death in the United States. The global market for cancer therapeutics is growing rapidly, with revenues projected to reach $161 billion in 2026. (source: Allied Market Research 2021).
Currently, the standard of care for solid tumor cancers in the U.S is surgery and radiation/chemotherapy. Patients face significant challenges as treatment regimens must factor in the patient’s ability to tolerate the commonly used chemotoxins.
Significant numbers of cancer patients seek new treatment options especially in recurrent disease. According to the American Cancer Society, this is especially true in glioblastoma, colorectal, pancreatic, ovarian, and small cell lung cancers.
We are founders, scientists, oncologists, biopharmaceutical experts, executives – and passionate people devoted to getting things done – hailing from start-up and multinational companies.
Driven by a shared mission, our team applies clarity, tenacity, and vision in our fight against cancer and the pursuit of new treatment options for patients and their families.
CEO &
Director
Interim CFO,
Director & Co-Founder
EVP - Clinical Operations, Director
& Co-Founder
EVP - Portfolio Management
Executive Director - Intellectual Property
Chairman Emeritus
Alset International
CEO &
Director
Interim CFO,
Director & Co-Founder
EVP -
Clinical Operations
Director
& Co-Founder
Managing Director,
Infusion 51a
Director &
Co-Founder
General Director, Infusion 51a
Founder, Sadanah Foundation
Director, Sadanah Trauma & Surgical Initiative
NSPC Spine & Brain Surgery
Long Island, NY
Clinical Neuro-Oncologist
Executive Board Member American
Cancer Society
Columbia University Irving Medical Center New York, NY John Harris Associate Professor of Neurology and Chief Neuro-Oncology, Columbia University Irving Medical Center
Department of Neurology
Duke University School of Medicine Durham, NC
Associate Professor of Neurosurgery
Director of Supportive Care
Dana-Farber Cancer
Institute: Harvard
School Boston, MA
Clinical Director,
Center for Neruo-Oncology
Novant Health Cancer Institute
Forsyth Medical Center
Winston-Salem, NC
Chair, IRB and Co-Chair, Neuro-Oncology Council
Duke University School of Medicine
Durham, NC
Professor of Medicine
Associate Director,
Duke Cancer Institute
HonorHealth Research Institute, University of Arizona College of Medicine
Scottsdale, AZ
Medical Oncology/Clinical Investigator
Clinical Assistant Professor,
Internal Medicine
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Eget rhoncus viverra tristique aliq uam et praesent adipiscing turpis auris.
1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980
2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.
3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680
4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)
5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997. https://www.jbc.org
6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org
